Ultime notizie per Pulmatrix (NASDAQ:PULM) Azioni

Pulmatrix

Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Pulmatrix Inc

Pulmonx Corp

BMO Capital analyst Keith Bachman maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Outperform and raises the price target from $233 to $295.

News

Price Target

Analyst Ratings

BMO Capital Maintains Outperform on Zscaler, Raises Price Target to $295

BMO Capital analyst Brian Pitz reiterates Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Outperform and raises the price target from $82 to $95.

Reiteration

RBLX

BMO Capital Reiterates Outperform on Roblox, Raises Price Target to $95

Several airline companies have added <a href="https://www.benzinga.com/topic/starlink">Starlink internet service</a> to their in-flight customers, adding the popular satellite internet offering from Elon Musk's SpaceX company.
A new Benzinga reader survey shows airlines that offer Starlink on flights could have an advantage as the internet service is becoming more popular.
What Happened: Starlink is used by <a href="https://www.benzinga.com/25/02/43964680/elon-musks-starlink-expands-at-35000-feetqatar-airways-equips-50-of-its-boeing-fleet-with-high-speed-satellite-wi-fi">millions of customers </a>at their homes and businesses across more than 100 countries, as of January.
The internet service is also becoming increasingly popular in the skies with airlines signing deals to offer free internet to their passengers or charge for the premium service that could have faster speed than existing Wi-Fi services.
Benzinga recently polled readers to see how important airlines offering Starlink is for flights.
"When booking a flight, how important is Starlink being offered as an internet service in making the airline selection?" Benzinga asked.
The results were:
<ul class="wp-block-list">
<li>Somewhat important, but not the most important booking determination: 43%</li>
<li>Not important, not a factor: 36%</li>
<li>Very important, won't fly without: 21%</li>
</ul>
The poll shows that 64% of readers said Starlink being on flights is somewhat important or very important and could be a determining factor in booking airlines.
Around one-third (36%) said that Starlink is not important and not a factor, a figure that could decline as more passengers experience Starlink internet and increased speeds over time.
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/25/05/45600269/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-66">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: SpaceX CEO Musk has suggested that Starlink will be available <a href="https://www.benzinga.com/news/23/10/35154382/musk-says-starlink-internet-could-soon-be-available-on-most-flights-but-theres-a-condition">on most flights</a> in the future, with the decision ultimately up to airline companies to carry the service.
Starlink has been used on over 55,000 flights across more than 110,000 in-flight hours and more than 55 million miles, according to the company's <a href="https://www.starlink.com/business/aviation">website</a>.
"Starlink has provided high-speed, low-latency internet on tens of thousands of flights and counting, keeping passengers connected from the moment they step onboard their aircraft and throughout their travels all around the world," the Starlink website reads.
Several airlines have announced deals with Starlink for in-flight internet services on a portion of their flights or all of their flights.
In North America, this list includes <a href="https://www.benzinga.com/25/03/44563126/united-airlines-to-launch-first-starlink-equipped-flight-in-may-faa-grants-approval">United Airlines Holdings</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>), WestJet, and <a href="https://www.benzinga.com/news/24/09/41023552/hawaiin-airlines-airbus-planes-take-flight-with-starlink-internet-service-at-no-additional-cost-to-c">Hawaiian Airlines,</a> which is now owned by Alaska Air Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>).
These stocks could have an advantage based on the survey result with more and more passengers seeking out flights that have Starlink as an option. United is rolling out Starlink to more of its flights and Alaska Air Group is looking to add Starlink to other plane units outside of just the Hawaiian Airlines brand. 
In other parts of the world, the list of airlines with Starlink includes Qatar Airways, Air New Zealand, Air France and airBaltic.
Musk recently said it was "possible that Starlink may go public at some point in the future." 
But while the billionaire also said there was "no rush to go public," readers are still interested in investing in the internet company and its parent, SpaceX.
In a <a href="https://www.benzinga.com/general/space/25/05/45680115/tesla-the-best-elon-musk-company-84-say-no-these-3-rank-higher">poll of Elon Musk-related companies</a>, Benzinga readers said they would most want to invest in Starlink (27%) or SpaceX with a minority ownership stake in Starlink (27%). These two units ranked ahead of other Musk-related companies such as X/xAI (19%), Tesla Inc (16%) and others.
The study was conducted by Benzinga from May 23, 2025, through May 27, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 113 adults.
Photo: Below the Sky via Shutterstock

Exclusives

EXCLUSIVE: Could Airlines With Starlink See Booking Boost? What Benzinga Reader Poll Says

BMO Capital analyst Keith Bachman maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Market Perform and raises the price target from $11.5 to $15.5.

PATH

BMO Capital Maintains Market Perform on UiPath, Raises Price Target to $15.5

BMO Capital analyst Ameet Thakkar maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Outperform and raises the price target from $381 to $522.

BMO Capital Maintains Outperform on GE Vernova, Raises Price Target to $522

BMO Capital analyst Thomas Martin maintains BRP (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DOO#TSX">DOO</a>) with a Outperform and raises the price target from C$70 to C$75.

TSX:DOO

BMO Capital Maintains Outperform on BRP, Raises Price Target to C$75

Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) posted better-than-expected earnings for the first quarter on Thursday.
Marvell reported quarterly adjusted earnings of 62 cents per share, which beat the Street estimate of 61 cents. Quarterly revenue came in at $1.9 billion, which beat the consensus estimate of $1.88 billion.
"Marvell delivered record revenue in the first quarter of $1.895 billion, a 63% year-over-year increase, and we are forecasting continued strong growth into the second quarter," said Matt Murphy, Marvell's CEO. "This momentum is being fueled by strong AI demand in the data center end market, where our revenue is benefiting from the rapid scaling of our custom silicon programs and robust shipments of our electro-optics products."
Marvell sees second-quarter net revenue of $2 billion, plus or minus 5%, and non-GAAP EPS of 67 cents, plus or minus five cents.
Marvell shares fell 6.9% to trade at $59.34 on Friday.
These analysts made changes to their price targets on Marvell following earnings announcement.
<ul class="wp-block-list">
<li>Needham analyst Quinn Bolton maintained Marvell Tech with a Buy and lowered the price target from $100 to $85.</li>
<li>Wells Fargo analyst Aaron Rakers maintained the stock with an Overweight rating and lowered the price target from $120 to $95.</li>
<li>Keybanc analyst John Vinh maintained the stock with an Overweight rating and lowered the price target from $115 to $90.</li>
<li>Piper Sandler analyst Harsh Kumar reiterated Marvell Tech with an Overweight rating and lowered the price target from $95 to $85.</li>
<li>Evercore ISI Group analyst Mark Lipacis maintained the stock with an Outperform rating and lowered the price target from $135 to $133.</li>
<li>Raymond James analyst Srini Pajjuri reiterated the stock with an Outperform rating and lowered the price target from $110 to $90.</li>
</ul>
Considering buying MRVL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MRVL/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30131758/image-420-1024x587.png" alt="" class="wp-image-933573" style="width:670px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30131758/image-420-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30131758/image-420-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30131758/image-420-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30131758/image-420.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45691209/top-3-materials-stocks-that-could-blast-off-this-month-2">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

MRVL

Marvell Technology Analysts Slash Their Forecasts After Q1 Earnings

BMO Capital analyst Sohrab Movahedi maintains Canadian Imperial Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CM#NYSE">CM</a>) with a Outperform and raises the price target from $98 to $102.

BMO Capital Maintains Outperform on Canadian Imperial Bank, Raises Price Target to $102

Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability progression and low disease activity levels for up to two years.
The latest <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2025-05-30" rel="noreferrer noopener">results</a> for this investigational Bruton&#8217;s tyrosine kinase (BTK) inhibitor from the Phase II FENopta open-label extension (OLE) study were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.
Ninety-nine patients entered the OLE and 93 remained in the OLE after 96 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45393806/ten-year-data-from-roches-breast-cancer-trial-shows-perjeta-based-regimen-cuts-death-risk-by-17" rel="noreferrer noopener">Ten-Year Data From Roche&#8217;s Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%</a>
During the OLE period, patients treated with fenebrutinib for up to 96 weeks had a low annualised relapse rate (ARR) of 0.06, and during this time there was no disability progression, as measured by the Expanded Disability Status Scale (EDSS).
MRI scans showed that fenebrutinib treatment suppressed disease activity in the brain. At 96 weeks zero new T1 gadolinium-enhancing (T1-Gd+) lesions, which are markers of active inflammation, were detected.
In the treatment group that switched from placebo to fenebrutinib in the OLE, the annualized rate of new or enlarging T2 lesions, which represent chronic disease burden, decreased from 6.72 at the end of the 12-week double-blind period to 0.34 by 96 weeks.
The safety profile of fenebrutinib in the OLE was consistent with previously reported data, with no new safety concerns identified at 96 weeks.
During the OLE, one patient experienced asymptomatic alanine aminotransferase elevation at OLE week 4, after 16 weeks on treatment, which resolved with treatment discontinuation.
Three Phase 3 trials are ongoing, including the FENhance 1 and 2 trials in RMS and the FENtrepid trial in primary progressive multiple sclerosis (PPMS). The first data from these studies are expected at the end of 2025.
In April, Roche announced it would invest $50 billion in the U.S. over&nbsp;the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44934942/roche-plans-50-billion-us-investment-over-5-years-with-12000-new-jobs" rel="noreferrer noopener">next five years</a>.
These investments further strengthen Roche&#8217;s already significant U.S. footprint, which includes 13 manufacturing and 15 R&amp;D sites across the Pharmaceutical and Diagnostics Divisions.
The investment is expected to&nbsp;<a target="_blank" href="https://www.roche.com/media/releases/med-cor-2025-04-22?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">create</a> over 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 jobs at new and expanded facilities.
Price Action: RHHBY stock is trading higher by 1.83% to $40.25 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45692578/regeneron-sanofi-stock-falls-after-uneven-smokers-lung-drug-data" target="_blank" rel="noreferrer noopener">Regeneron, Sanofi Stock Falls After Uneven Smoker&#8217;s Lung Drug Data</a></li>
</ul>
Photo by OleksSH via Shutterstock

Health Care

RHHBY

Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years

<a href="https://www.bloomberg.com/news/articles/2025-05-30/tsmc-is-said-to-evaluate-building-advanced-chip-plant-in-the-uae" title="https://www.bloomberg.com/news/articles/2025-05-30/tsmc-is-said-to-evaluate-building-advanced-chip-plant-in-the-uae">https://www.bloomberg.com/news/articles/2025-05-30/tsmc-is-said-to-evaluate-building-advanced-chip-plant-in-the-uae</a>

Global

'TSMC Is Said To Weigh Building Advanced Chip Plant In The UAE' - Bloomberg News

Raymond James analyst Olivia Tong reiterates Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Outperform and raises the price target from $450 to $500.

ULTA

Raymond James Reiterates Outperform on Ulta Beauty, Raises Price Target to $500

Raymond James analyst Brent Penter reiterates Starz Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRZ#NASDAQ">STRZ</a>) with a Outperform and raises the price target from $19 to $22.

STRZ

Raymond James Reiterates Outperform on Starz Entertainment, Raises Price Target to $22

Rivian Automotive Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) shares have been volatile in recent sessions amid broader EV market turbulence, despite long-term optimism surrounding its upcoming R2 model. 
What To Know: The recent downturn across EV stocks follows the House passage of President Donald Trump's "Big Beautiful Bill," which <a href="https://www.benzinga.com/25/05/45586258/is-trumps-big-beautiful-bill-a-major-roadblock-for-elon-musks-tesla-and-other-evs">proposes eliminating</a> the $7,500 federal EV tax credit for high-volume automakers, among other policy rollbacks.
Despite this political uncertainty, analysts are <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45617151/ubs-maintains-neutral-rating-for-rivian-stock-sets-price-13-price-target">cautiously optimistic</a> about Rivian. UBS raised its price target from $12 to $13, maintaining a Neutral rating, citing the affordable R2 SUV, slated for 2026 with a ~$45,000 price tag, as a key growth driver. 
CEO RJ Scaringe this week <a href="https://www.benzinga.com/25/05/45642153/rivian-ceo-rj-scaringe-touts-45000-rivian-r2s-updated-rear-suspension-cant-wait-for-folks">showcased</a> the R2&#8217;s innovative multi-link rear suspension, emphasizing cost-efficient engineering and enhanced ride quality.
Rivian is also investing $120 million to expand its Illinois facility, potentially adding hundreds of jobs. A $5.8 billion collaboration with Volkswagen to build a budget EV further strengthens its strategic outlook. 
While tariff concerns have led Rivian to cut its 2025 delivery forecast, a strong first-quarter performance and growing investor confidence keep the stock on steadier footing.
Read Also: <a href="https://www.benzinga.com/cannabis/25/05/45698481/galaxy-digital-glxy-shares-slide-5-following-upsized-public-offering-announcement">Galaxy Digital Shares Slide 5% Following Upsized Public Offering Announcement</a> Price Action: RIVN shares are trading lower by 2.6% to $14.62 Friday afternoon. The stock is lower by 5.8% over the trailing week.
<h2 class="wp-block-heading">How To Buy RIVN Stock</h2>
By now you're likely curious about how to participate in the market for Rivian Automotive &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Rivian Automotive, which is trading at $14.83 as of publishing time, $100 would buy you 6.74 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, RIVN has a 52-week high of $18.86 and a 52-week low of $9.50.
Image: Shutterstock

RIVN

Rivian (RIVN) Stock Is Volatile: What's Going On?

Raymond James analyst Srini Pajjuri reiterates Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Outperform and lowers the price target from $110 to $90.

Raymond James Reiterates Outperform on Marvell Tech, Lowers Price Target to $90

<a href="https://www.bloomberg.com/news/articles/2025-05-30/rivian-eyes-new-debt-deal-as-expected-vehicle-deliveries-slump?srnd=homepage-americas&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-30/rivian-eyes-new-debt-deal-as-expected-vehicle-deliveries-slump?srnd=homepage-americas&amp;embedded-checkout=true</a>

General

'Rivian Eyes New Debt Deal as Expected Vehicle Deliveries Slump'- Bloomberg

Raymond James analyst Simon Leopold maintains Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) with a Outperform and raises the price target from $144 to $150.

DELL

Raymond James Maintains Outperform on Dell Technologies, Raises Price Target to $150

Raymond James analyst John Freeman reiterates APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Outperform and raises the price target from $23 to $25.

Raymond James Reiterates Outperform on APA, Raises Price Target to $25

Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) stock is trading higher Friday after the company reported better-than-expected first-quarter financial results on Thursday after the market closed and raised its fiscal-<a href="https://www.benzinga.com//node/45680852">year 2025 guidance</a>.
What To Know: The company posted adjusted earnings per share of 84 cents, beating the consensus estimate of 75 cents. In addition, Zscaler, reported sales of $678.03 million, beating the consensus estimate of $666.86 million, and representing a 23% year-over-year climb.
The company ended the quarter with $3.0 billion in cash and cash equivalents, an increase of $595.9 million, compared to the same time period last year.
&#8220;We delivered outstanding&nbsp;Q3&nbsp;results as an increasing number of customers adopt our expanding Zero Trust Exchange platform. We enable customers to realize Zero Trust Everywhere while lowering operational cost and complexity,&#8221; said Jay Chaudhry, Chairman and CEO of Zscaler.&nbsp;
Zscaler announced that it appointed Kevin Rubin as CFO. Rubin is set to succeed Remo Canessa, who announced plans to retire last year.
Outlook: The company sees fourth-quarter sales of $705 million to $707 million, versus the consensus estimate of $707.61 million. For fiscal-year 2025, Gap now sees adjusted earnings per share from $3.18 to $3.19, versus the consensus estimate of $3.07.
The company previously anticipated adjusted earnings per share from $3.04 to $3.09. Gap now expects sales of $2.66 billion, versus the consensus estimate of $2.65 billion. It previously saw sales from $2.64 billion to $2.65 billion.
Analyst Changes: Following the earnings report, multiple analysts announced price target adjustments.
<ul class="wp-block-list">
<li>JMP Securities analyst Trevor Walsh maintained a Market Outperform rating and raised the price target from $240 to $310.</li>
<li>Keybanc analyst Eric Heath maintained an Overweight rating and raised the price target from $290 to $310.</li>
<li>UBS analyst Roger Boyd maintained a Buy rating and raised the price target from $260 to $315.</li>
<li>Wells Fargo analyst Andrew Nowinski maintained an Equal-Weight rating and raised the price target from $210 to $260.</li>
</ul>
Related Link: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45695903/ulta-stock-is-rising-friday-whats-going-on">Ulta Stock Is Rising Friday: What&#8217;s Going On?</a>
ZS Price Action: At the time of publication, Zscaler stock is trading 8.53% higher at $272.63, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjTpP_ircuNAxVCpIkEHV7jF6UQFnoECAsQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro.</a>
Image: via Shutterstock

Movers

Zscaler Stock Is Gaining Friday: What's Going On?

Evercore ISI Group analyst Peter Levine maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Outperform and raises the price target from $245 to $290.

Evercore ISI Group Maintains Outperform on Zscaler, Raises Price Target to $290

Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) posted better-than-expected earnings for the <a href="https://www.benzinga.com/quote/BURL/earnings">first quarter on Thursday</a>.
The company reported first-quarter adjusted earnings per share of $1.60, beating the analyst consensus estimate of $1.41. Quarterly sales of $2.50 billion missed the Street view of $2.52 billion.
"We anticipate that tariffs will put significant pressure on our merchandise margin, but we are confident that, as long as tariffs do not increase from current levels, we can offset this pressure elsewhere in the P&amp;L," said the company's CEO Michael O'Sullivan.
Burlington Stores sees second-quarter adjusted EPS of $1.20-$1.30 versus the $1.34 estimate. The firm expects total sales to increase in the range of 5% to 7%; this assumes comparable store sales will increase in the range of 0% to 2%.
For FY25, the firm expects total sales to increase in the range of 6% to 8% on top of the 11% increase during Fiscal 2024.
Burlington shares fell 0.7% to trade at $226.17 on Friday.
These analysts made changes to their price targets on Burlington following earnings announcement.
<ul class="wp-block-list">
<li>Telsey Advisory Group analyst Dana Telsey maintained Burlington Stores with an Outperform rating and lowered the price target from $340 to $300.</li>
<li>Barclays analyst Adrienne Yih maintained the stock with an Overweight rating and raised the price target from $254 to $299.</li>
<li>Evercore ISI Group analyst Michael Binetti maintained Burlington Stores with an Outperform rating and lowered the price target from $345 to $310.</li>
</ul>
Considering buying BURL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/BURL/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="535" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30130608/image-419-1024x535.png" alt="" class="wp-image-933555" style="width:683px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30130608/image-419-1024x535.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30130608/image-419-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30130608/image-419-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30130608/image-419.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45691209/top-3-materials-stocks-that-could-blast-off-this-month-2">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

Comments

Pulmatrix

Notizie

Ultime notizie per Pulmatrix (NASDAQ:PULM) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO